nadE from Streptococcus pneumoniae

Details nadE from Streptococcus pneumoniae nadE from Streptococcus pneumoniae

1999-02-16

2001-06-26

Mertz, Prema (Department: 1646)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S071100, C435S071200, C435S471000, C435S320100, C435S252300, C435S254110, C536S023100, C536S023200, C536S024300, C536S024320, C530S350000

Reexamination Certificate

active

06251631

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, the invention relates to polynucleotides and polypeptides of the NAD biosynthesis family, as well as their variants, herein referred to as “nadE,” “nadE polynucleotide(s),” and “nadE polypeptide(s)” as the case may be.
BACKGROUND OF THE INVENTION
The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid. Since its isolation more than 100 years ago,
Streptococcus pneumoniae
has been one of the more intensively studied microbes. For example, much of our early understanding that DNA is, in fact, the genetic material was predicated on the work of Griffith and of Avery, Macleod and McCarty using this microbe. Despite the vast amount of research with
S. pneumoniae
, many questions concerning the virulence of this microbe remain. It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics.
The frequency of
Streptococcus pneumoniae
infections has risen dramatically in the past few decades. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate
Streptococcus pneumoniae
strains that are resistant to some or all of the standard antibiotics. This phenomenon has created an unmet medical need and demand for new anti-microbial agents, vaccines, drug screening methods, and diagnostic tests for this organism.
Moreover, the drug discovery process is currently undergoing a fundamental revolution as it embraces “functional genomics,” that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on “positional cloning” and other methods. Functional genomics relies heavily on the various tools of bioinforrnatics to identify gene sequences of potential interest from the many molecular biology databases now available as well as from other sources. There is a continuing and significant need to identify and characterize further genes and other polynucleotides sequences and their related polypeptides, as targets for drug discovery.
Clearly, there exists a need for polynucleotides and polypeptides, such as the nadE embodiments of the invention, that have a present benefit of, among other things, being useful to screen compounds for antimicrobial activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists to find ways to prevent, ameliorate or correct such infection, dysfunction and disease.
SUMMARY OF THE INVENTION
The present invention relates to nadE, in particular nadE polypeptides and nadE polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including treatment of microbial diseases, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists using the materials provided by the invention, and for treating microbial infections and conditions associated with such infections with the identified agonist or antagonist compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with microbial infections and conditions associated with such infections, such as assays for detecting nadE expression or activity.
Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.
DESCRIPTION OF THE INVENTION
The invention relates to nadE polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a nadE of
Streptococcus pneumoniae
, that is related by amino acid sequence homology to NADE
—
ECOLI
NH(3)-DEPENDENT NAD(+) SYNTHETASE
(NITROGEN-REGULATORY PROTEIN) polypeptide. The invention relates especially to nadE having a nucleotide and amino acid sequences set out in Table 1 as SEQ ID NO:1 and SEQ ID NO:2 respectively. Note that sequences recited in the Sequence Listing below as “DNA” represent an exemplification of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including ribopolynucleotides.
TABLE 1
NadE Polynucleotide and Polypeptide Sequences
(A)
Streptococcus pneumoniae
nadE
polynucleotide sequence [SEQ ID NO:1].
5′-

ATGAGTTTGCAAGAAACGATTATCCAAGAGCTGGGTGTCAAACCAGTGA

TTGATGCCCAGGAAGAAATCCGTCGTTCTATTGATTTCTTAAAAAGATA

TCTGAAAAAACATCCCTTCCTAAAAACCTTTGTACTAGGGATTTCTGGG

GGACAAGACTCAACCTTGGCAGGACGTTTGGCGCAATTAGCTATGGAAG

AACTGCGAGCTGAAACGGGAGACGATAGCTACAAATTTATCGCTGTCCG

CCTGCCATACGGAGTGCAAGCTGATGAAGCAGATGCTCAAAAAGCCCTA

GCCTTCATCCAGCCAGATGTCAGCTTGGTTGTGAATATCAAGGAATCAG

CTGATGCCATGACAGCTGCAGTTGAAGCGACAGGTAGTCCTGTTTCAGA

CTTCAACAAGGGGAATATCAAGGCACGTTGCCGTATGATTGCTCAGTAT

GCCCTTGCTGGTTCCCATAGCGGAGCGGTCATTGGAACAGACCACGCCG

CAGAAAATATCACAGGTTTCTTTACCAAGTTTGGTGACGGCGGTGCGGA

TATTCTCCCTCTTTACCGCCTCAATAAACGCCAAGGAAAACAGCTCTTG

CAGAAACTTGGCGCAGAGCCAGCCCTTTATGAAAAAATCCCAACGGCAG

ACCTAGAAGAAGATAAACCAGGCCTAGCTGACGAAGTCGCACTTGGAGT

CACCTACGCAGAGATTGACGACTACCTAGAAGGCAAAACAATCAGCCCA

GAAGCTCAAGCGACCATTGAAAACTGGTGGCACAAAGGCCAACACAAAC

GCCACTTACCCATCACCGTATTTGATGACTTTTGGGAGTAA-3′
(B)
Streptococcus pneumoniae
nadE polypeptide
sequence deduced from a polynucleotide sequence
in this table [SEQ ID NO:32].
NH
2
-

MSLQETIIQELGVKPVIDAQEEIRRSIDFLKRYLKKHPFLKTFVLGISG

GQDSTLAGRLAQLAMEELRAETGDDSYKFIAVRLPYGVQADEADAQKAL

AFIQPDVSLVVNIKESADAMTAAVEATGSPVSDFNKGNIKARCRMIAQY

ALAGSHSGAVIGTDHAAENITGFFTKFGDGGADILPLYRLNKRQGKQLL

QKLGAEPALYEKIPTADLEEDKPGLADEVALGVTYAEIDDYLEGKTISP

EAQATIENWWHKGQHKRHLPITVFDDFWE-COOH
Deposited Materials
A deposit comprising a
Streptococcus pneumoniae
0100993 strain has been deposited with the National Collections of Industrial and Marine Bacteria Ltd. (herein “NCIMB”), 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland on Apr. 11, 1996 and assigned deposit number 40794. The deposit was described as
Streptococcus pneumoniae
0100993 on deposit. On Apr. 17, 1996 a
Streptococcus pneumoniae
0100993 DNA library in
E. coli
was similarly deposited with the NCIMB and assigned deposit number 40800. The
Streptococcus pneumoniae
strain deposit is referred to herein as “the deposited strain” or as “the DNA of the deposited strain.”
The deposited strain comprises a full length nadE gene. The sequence of the polynucleotides comprised in the deposited strain, as well as the amino acid sequence of any polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.
The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The deposited strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. §112. A license may be required to make, use or sell the deposited strain, and compounds derived therefrom, and no such license is hereby granted.
In one aspect of the inve

Affiliated with

Also associated with

Rating

nadE from Streptococcus pneumoniae does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with nadE from Streptococcus pneumoniae, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and nadE from Streptococcus pneumoniae will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2512222